1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B4B596BCE8E7FB0D85256FCF0059F578
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/communicating-clinical-study-results-for-maximum-impact?opendocument
18
19opendocument
2054.166.133.84
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RC




Products & Services

Communicating Clinical Study Results for Maximum Impact

ID: WP-14


Pages: 9


Published: Pre-2013


Delivery Format: Online


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download White Paper

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
This white paper is an excerpt from research profiling top pharmaceutical companies that successfully communicate landmark clinical studies findings in ways that boost marketing efforts. Information was gathered through extensive surveys and interviews with executives working in marketing and medical affairs departments. Best Practices, LLC analysts employed qualitative and quantitative research methods to identify and probe the winning strategies and tactics that immortalize study results in the minds of physicians and patients.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic


Companies Profiled:
Abbott; Sanofi-aventis; AstraZeneca; Eli Lilly; GlaxoSmithKline; Merck; Schering-Plough